These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 9736576)
21. Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model. Zelenitsky SA; Booker B; Laing N; Karlowsky JA; Hoban DJ; Zhanel GG Antimicrob Agents Chemother; 1999 Mar; 43(3):592-7. PubMed ID: 10049272 [TBL] [Abstract][Full Text] [Related]
22. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Seral C; Van Bambeke F; Tulkens PM Antimicrob Agents Chemother; 2003 Jul; 47(7):2283-92. PubMed ID: 12821480 [TBL] [Abstract][Full Text] [Related]
23. In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates. García-Garrote F; Cercenado E; Alcalá L; Bouza E Antimicrob Agents Chemother; 1998 Sep; 42(9):2452-5. PubMed ID: 9736584 [TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Hanberger H; Nilsson LE; Maller R; Isaksson B Antimicrob Agents Chemother; 1991 Sep; 35(9):1710-6. PubMed ID: 1659305 [TBL] [Abstract][Full Text] [Related]
25. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Arthur M; Depardieu F; Reynolds P; Courvalin P Antimicrob Agents Chemother; 1999 Aug; 43(8):1875-80. PubMed ID: 10428906 [TBL] [Abstract][Full Text] [Related]
26. In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci. Al-Nawas B; Swantes J; Shah PM Infection; 2000; 28(4):214-8. PubMed ID: 10961526 [TBL] [Abstract][Full Text] [Related]
27. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus. Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792 [TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections. Garcia LG; Lemaire S; Kahl BC; Becker K; Proctor RA; Denis O; Tulkens PM; Van Bambeke F Antimicrob Agents Chemother; 2012 Jul; 56(7):3700-11. PubMed ID: 22564838 [TBL] [Abstract][Full Text] [Related]
32. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. Vaudaux P; Huggler E; Bernard L; Ferry T; Renzoni A; Lew DP Antimicrob Agents Chemother; 2010 Sep; 54(9):3861-70. PubMed ID: 20547791 [TBL] [Abstract][Full Text] [Related]
33. Effect of human plasma on the antimicrobial activity of iclaprim in vitro. Laue H; Valensise T; Seguin A; Hawser S; Lociuro S; Islam K J Antimicrob Chemother; 2007 Dec; 60(6):1388-90. PubMed ID: 17951265 [TBL] [Abstract][Full Text] [Related]
34. Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains. Zelenitsky SA; Karlowsky JA; Zhanel GG; Hoban DJ; Nicas T Antimicrob Agents Chemother; 1997 Jun; 41(6):1407-8. PubMed ID: 9174212 [No Abstract] [Full Text] [Related]
35. Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa. Kussmann M; Hauer S; Pichler P; Reznicek G; Burgmann H; Poeppl W; Zeitlinger M; Wiesholzer M Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1091-1098. PubMed ID: 29546637 [TBL] [Abstract][Full Text] [Related]
36. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Bailey EM; Rybak MJ; Kaatz GW Antimicrob Agents Chemother; 1991 Jun; 35(6):1089-92. PubMed ID: 1834010 [TBL] [Abstract][Full Text] [Related]
37. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Kebriaei R; Rice SA; Stamper KC; Rybak MJ Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436 [TBL] [Abstract][Full Text] [Related]
38. Teicoplanin combined with various antibiotics and human blood against a multiple-drug-resistant strain of Staphylococcus aureus. Traub WH; Spohr M; Bauer D Chemotherapy; 1991; 37(3):186-95. PubMed ID: 1832374 [TBL] [Abstract][Full Text] [Related]
39. Stability studies with tigecycline in bacterial growth medium and impact of stabilizing agents. Amann LF; Vicente ER; Rathke M; Broeker A; Riedner M; Wicha SG Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):215-218. PubMed ID: 32720091 [TBL] [Abstract][Full Text] [Related]
40. Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies. Stratton CW; Weeks LS Diagn Microbiol Infect Dis; 1990; 13(3):245-52. PubMed ID: 2166634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]